Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors

Solid Tumors Clinical Trial

Official title:

An Open-Label, Phase 1/1b, Single-Agent Study of RXDX-105 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01877811
• Other study ID #: RXDX-105-01
• Status: Completed
• Phase: Phase 1
• Start date: June 2013
• Est. completion date: February 2019

Study information

• Verified date: April 2019
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a first-in-human, multicenter, open-label study consisting of 2 phases. Phase 1 is a dose escalation study of RXDX-105 (formerly known as CEP-32496) in patients with advanced solid tumors aimed at defining the recommended Phase 2 dose (RP2D) and schedule for administration. Phase 1b is a dose expansion in approximately 90 patients with advanced solid tumors with specific histologies and/or molecular alterations of interest. Patients in Phase 1b will be treated at the RP2D determined in Phase 1.

Description:

The primary objective of Phase 1 is to determine the recommended Phase 2 dose (RP2D) of RXDX-105. The primary objective of Phase 1b is to further assess the safety profile and tolerability of RXDX-105 at the RP2D The secondary objective is to evaluate the antitumor activity of RXDX-105 at the RP2D, as assessed by objective response rate (ORR) (complete response [CR] or partial response [PR]) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) in patients with advanced solid tumors with RET or BRAF mutations or rearrangements.

The RP2D has been determined and Phase 1 portion of the study is now closed to new patient enrollment.

Phase 1 b is open and enrolling patients with solid tumors harboring a RET rearrangement or mutation, or a BRAF rearrangement or mutation. Additionally, patients with Squamous NSCLC and lung adenocarcinomas with other alterations than RET or BRAF such as KRAS mutations, etc. will also be enrolled. Approximately 90 patients will be enrolled in Phase 1b.

Each phase of this study will consist of a 28-day screening period. Patients will be treated in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment. Patients in Phase 1 and 1b will be followed for 6 months after the last dose of study treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 143
• Est. completion date: February 2019
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria for Phase 1b:

1. Patients must have histologically or cytologically confirmed advanced solid tumors with a histology and/or molecular alteration of interest as defined in Section 4, detected by a CLIA-certified or equivalently accredited diagnostic laboratory

• Squamous NSCLC and Non-squamous NSCLC (no known RET alterations or BRAF V600E mutations) patients must have archival tissue available for analysis by Ignyta; all other patients must send tissue to Ignyta, if tissue is available

2. Prior Treatment:

• Patients with BRAF V600E mutations must be TKI-naïve; any number of other prior therapies are allowed

• NSCLC patients with RET alterations who have had a prior RET inhibitor or are RET inhibitor-naïve will be enrolled; (any number of other prior therapies are allowed); all other histologies with RET alterations must be RET inhibitor-naïve

• Patients with Squamous NSCLC and Non-squamous NSCLC (no known RET alterations or BRAF V600E mutations) may have had prior TKIs and any number of other prior therapies

3. Measurable disease according to RECIST v1.1 for all patients except patients with RET altered tumors; patients with RET altered tumors must have evaluable disease, but are not required to have measurable disease

4. Patients with treated, stable CNS metastases, including leptomeningeal carcinomatosis are allowed. The use of seizure prophylaxis is allowed. Patients requiring steroids must be at a stable or decreasing dose for at least 2 weeks prior to the start of RXDX-105 treatment.

5. Eastern Cooperative Oncology Group (ECOG) performance status = 2

6. Able to ingest oral medication

7. Other inclusion criteria apply

Exclusion Criteria for Phase 1b:

1. Treated with systemic anticancer therapy or an investigational agent within 2 weeks or 5 half-lives, whichever is shorter, prior to start of study drug treatment (4 weeks for antibody therapy and immunotherapy, and 2 weeks for bevacizumab in colon cancer patients)

2. Major surgery 21 days or less prior to starting study drug or has not recovered from adverse effects of such therapy

3. Radiotherapy within 2 weeks prior to start of study drug treatment (palliative radiation or stereotactic radiosurgery within 7 days prior to start of study treatment). Patients must have recovered from all radiotherapy-related toxicities

4. History of non-pharmacologically induced prolonged QTc interval (e.g., repeated demonstration of a QTc interval > 500 milliseconds from ECGs performed at least 24 hours apart)

5. Major active infection requiring parenteral antibiotics

6. Severe or unstable medical condition, such as congestive heart failure (New York Heart Association [NYHA] Class III or IV), ischemic heart disease, uncontrolled hypertension, uncontrolled diabetes mellitus, psychiatric condition, as well as an uncontrolled cardiac arrhythmia requiring medication (= Grade 2, according to NCI CTCAE v4.03), myocardial infarction within 6 months prior to starting study treatment, or any other significant or unstable concurrent medical illness that in the opinion of the Investigator would preclude protocol therapy

7. History of other previous cancer that would interfere with the determination of safety or efficacy of RXDX-105 with respect to the qualifying solid tumor malignancy

8. Known infection with human immunodeficiency virus (HIV) and active hepatitis B or hepatitis C

9. Current participation in another clinical study of an investigational agent, vaccine, or device. Concomitant participation in observational studies is acceptable

10. Presence of a significant gastrointestinal disorder that, in the opinion of the Investigator or Sponsor, could interfere with absorption of RXDX-105 (e.g., malabsorption syndrome, gastrointestinal surgery)

11. Known hypersensitivity to any of the components of RXDX-105

Related Conditions & MeSH terms

• Solid Tumors

Intervention

Drug:
• RXDX-105
During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day. During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment.

Locations

Country	Name	City	State
United States	University Cancer & Blood Center, LLC	Athens	Georgia
United States	Massachusetts General Hospital/Beth Israel Deaconess Med. Ctr./Dana Farber Cancer Institute	Boston	Massachusetts
United States	Henry Ford Health System	Detroit	Michigan
United States	Karmanos Cancer Center	Detroit	Michigan
United States	City of Hope	Duarte	California
United States	University of Texas MD Anderson Cancer Center	Houston	Texas
United States	University of California Irvine College of Medicine	Irvine	California
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania
United States	Washington University	Saint Louis	Missouri
United States	University of California San Diego Moores Cancer Center	San Diego	California
United States	Florida Cancer Center	Sarasota	Florida
United States	University of Washington, Seattle Cancer Care Alliance	Seattle	Washington
United States	Lombardi Comprehensive Cancer Center, Georgetown	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1: Dose Limiting Toxicities	From signing of the informed consent up to approximately 12 months	Approximately 12 months
Primary	Phase 1: Occurrence of Adverse Events	From signing of the informed consent up to approximately 12 months	Approximately 12 months
Primary	Phase 1b: Occurrence of Adverse Events	To further assess the safety profile and tolerability of RXDX-105 at the RP2D	Approximately 12 months
Secondary	Phase 1: Maximum observed plasma drug concentration (Cmax)		Day 1 to Day 16
Secondary	Phase 1: Time of maximum observed plasma drug concentration (tmax)		Day 1 to Day 16
Secondary	Phase 1: Area under the plasma drug concentration versus time curve from time 0 to infinity (AUC0-8)		Day 1 to Day 16
Secondary	Phase 1: Area under the plasma drug concentration versus time curve from time 0 to the last measureable drug concentration (AUC0-t)		Day 1 to Day 16
Secondary	Phase 1: Area under the plasma drug concentration versus time curve from time 0 to 24 hours after study drug administration (AUC0-24)		Day 1 to Day 16
Secondary	Phase 1: Terminal elimination rate constant (?z)		Day 1 to Day 16
Secondary	Phase 1: Terminal elimination half-life (t1/2)		Day 1 to Day 16
Secondary	Phase 1: Apparent clearance of study drug from plasma (CL/F)		Day 1 to Day 16
Secondary	Phase 1b: Objective Response Rate	Objective response rate is defined as the proportion of patients with advanced solid tumors achieving best overall response of complete response (CR), or partial response (PR), as assessed using RECIST v1.1	Approximately 12 months
Secondary	Phase 1b: Duration of Objective Response	The duration of objective response is defined as the time interval from the date of first documented response (CR or PR) to disease progression or death, whichever occurs first	Approximately 12 months
Secondary	Phase 1b: Clinical Benefit Rate	Clinical benefit rate is defined as the proportion of patients achieving a complete response (CR), partial response (PR) or stable disease (SD) for 6 months	Approximately 12 months